SSTR2 and neuroendocrine neoplasm: Among these, 177Lu-Oxodotreotide (177Lu-DOTATATE, Lutathera®) is a radioligand therapy (RLT) that facilitates the precision treatment of neuroendocrine neoplasms (NENs) by selectively binding to somatostatin receptor 2 (SSTR2) [14,15,16].